1. Home
  2. JVA vs MDXH Comparison

JVA vs MDXH Comparison

Compare JVA & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JVA

Coffee Holding Co. Inc.

HOLD

Current Price

$3.53

Market Cap

17.8M

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.46

Market Cap

21.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JVA
MDXH
Founded
1971
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
21.1M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
JVA
MDXH
Price
$3.53
$0.46
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
48.1K
228.8K
Earning Date
06-12-2026
05-14-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
$90,655,294.00
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
$10.70
N/A
Revenue Growth
17.54
N/A
52 Week Low
$2.93
$0.40
52 Week High
$5.62
$5.33

Technical Indicators

Market Signals
Indicator
JVA
MDXH
Relative Strength Index (RSI) 52.51 52.68
Support Level $3.26 $0.40
Resistance Level $3.57 $3.79
Average True Range (ATR) 0.12 0.03
MACD 0.03 0.02
Stochastic Oscillator 87.14 87.60

Price Performance

Historical Comparison
JVA
MDXH

About JVA Coffee Holding Co. Inc.

Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: